Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...

The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.

A £520 million investment for manufacturing capacity was announced by Chancellor of the Exchequer, Rachel Reeves, but academic and industry leaders stress the money should be used to train personnel.

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

A genetic medicines customer has selected the company’s binders for commercial development of the customer’s product. Aptamer Group announced on Nov. 7, 2024 that one of its customers has advanced use ...

The complexities of tech transfer may be overcome by data-driven approaches, digital tools, and effective communication.

The product license holder must have a supplier oversight system in place, says Siegfried Schmitt, PhD, vice president, ...

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry ...

This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic ...

Recent hurricanes in the US close Baxter plant, shining a spotlight on supply chain fragility again.

Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.

Marianna Tcherpakov, PhD, director of Business Development, CMC Services, at Frontage Laboratories, spoke on the CDMO’s role in tackling complex technical challenges to enable startup biotechs solve ...